New York, Jan 6, 2026, 15:31 EST — Regular session
- Liquidia shares fell about 6% in afternoon trading after a Needham “Conviction List” change, a report said
- The drop contrasted with gains in biotech ETFs, pointing to a stock-specific move
- Investors are watching Yutrepia demand signals and the next quarterly update expected in March
Shares of Liquidia Corp (LQDA) fell 6.2% to $30.17 in afternoon trading on Tuesday after Needham removed the stock from its 2026 “Conviction List,” a report said. The shares hit a session low of $29.47, down from Monday’s close of $32.15.
The decline stood out against a firmer biotech backdrop. The SPDR S&P Biotech ETF was up about 1.1% and the iShares Nasdaq Biotechnology ETF gained about 2.0%.
For Liquidia, sentiment often tracks expectations for Yutrepia, its inhaled treprostinil powder used to treat pulmonary arterial hypertension (PAH), a form of high blood pressure in the lungs, and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia said it began shipping Yutrepia in June 2025 after a May 23 U.S. approval, and reported $51.7 million in third-quarter 2025 net product sales; Chief Executive Roger Jeffs said the quarter showed “continued momentum” in the launch. SEC
Yutrepia competes with United Therapeutics’ Tyvaso DPI, another treprostinil product delivered through a portable device. Liquidia’s path to market was shaped by years of legal and regulatory disputes tied to United’s franchise and protections that had kept Liquidia’s product off shelves before its full approval.
KalVista Pharmaceuticals shares were up 0.5% on Tuesday. Needham analyst Serge Belanger set a $32 price target on KalVista the same day, according to Quiver Quantitative data.
Investors are also watching cash needs as Liquidia scales Yutrepia’s commercial push. The company said in 2024 it deferred a one-time $23.8 million payment to HealthCare Royalty into two equal installments due in January and July 2026. Nasdaq
But the stock remains sensitive to execution risk. Any sign of slower prescription growth, tougher insurer coverage, or an adverse court development that limits sales would pressure revenue expectations and keep volatility high.
